Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206426 · ClinicalTrials.gov registry record
Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 79
- Enrollment target
NCT01206426 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 79 participants.
The verdict
NCT01206426 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
This is observational clinical trial to study adult urothelial cancer patients treated with cisplatin-based neoadjuvant chemotherapy. Hypothesis: Identification of genetic and molecular "cisplatin susceptibility" biomarkers will allow identification of urothelial cancer patients most likely to benefit from cisplatin-based neoadjuvant chemotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2009-10 |
| Est. Completion | 2017-10-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01206426
The ClinicalTrials.gov registry entry for NCT01206426 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01206426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01206426 about?
NCT01206426 is a clinical study titled "Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer". This is observational clinical trial to study adult urothelial cancer patients treated with cisplatin-based neoadjuvant chemotherapy. Hypothesis: Identification of genetic and molecular "cisplatin susceptibility" biomarkers will allow identification of urothelial cancer patients most likely to bene...
What is the current status of trial NCT01206426?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2009-10. Estimated completion is 2017-10-16.
Who is sponsoring clinical trial NCT01206426?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.